stockrowWhat it does
AptarGroup designs and manufactures devices and components that help dispense, deliver or protect medicines and consumer products. Founded in 1992 and headquartered in Crystal Lake, Illinois, the company is led by President and CEO Gael Touya.
For pharmaceutical customers, Aptar makes nasal spray pumps, inhaler valves and components used in injectable medicines. Its vial stoppers and syringe components sit in direct contact with drug products. It also sells materials designed to protect medicines and medical devices from moisture and other sources of degradation, as well as digital tools that help patients manage treatment and allow care teams to monitor them remotely.
For consumer-product companies, Aptar makes pumps for fragrances, lotions and other liquids; aerosol valves for pressurized containers; and dispensing closures used on food, beverages and personal care products. These components can control how a product comes out of its package without requiring the consumer to remove the cap.
Aptar works with customers on product design and manufacturing, using capabilities that include plastics molding, materials science and high-speed assembly. In pharma, it also provides services intended to help customers develop drug delivery devices and obtain regulatory approvals. Its operations are organized into Pharma, Beauty and Closures segments.
How it makes money
2025 reported net sales: $3.78 billion. Q3 2026 reported sales: just over $1 billion.
Aptar earns revenue by selling dispensing systems, drug delivery devices, packaging components and related services. It also receives customer royalties. CEO Gael Touya described Pharma as having approximately 90% generally growing repeat revenue.
Pharma sells devices and components for prescription medicines, consumer health care and injectables, along with active-material and digital health solutions. Its products include nasal pumps, metered-dose inhaler valves and syringe components. Pharma represented approximately 46% of net sales and accounted for 69% of Adjusted EBITDA excluding non-allocated corporate costs in 2025. Its 2025 reported net sales were $1.74 billion.
Beauty supplies pumps, airless systems and valves for fragrance, facial skincare, cosmetics, personal care and home care. It represented 35% of 2025 net sales, with reported net sales of $1.31 billion. Closures sells dispensing caps and sealing solutions across food, beverage and other consumer markets, as well as food service trays. It represented 19% of 2025 net sales, with reported net sales of $730.3 million.
Pricing can reflect changes in input costs and customer contracts. Aptar attempts to offset higher costs through productivity improvements, new products and price increases when market conditions or contracts allow. In Q3 2026, pass-throughs of higher input costs contributed approximately half of core sales growth in both Beauty and Closures. Aptar also reported that pricing adjustments to secure longer-term contracts affected Pharma sales in 2025.
Customers and how it sells
Aptar sells to pharmaceutical and health care companies as well as businesses in fragrance, cosmetics, personal care, home care, food and beverages. Its products become part of the finished packages or delivery systems those customers offer to patients and consumers. Pharma customers can work with Aptar from the molecular development stage of a medicine through its eventual distribution.
The company had approximately 5,000 customers, with no single customer or group of affiliated customers accounting for greater than 4% of 2025 Net Sales. Named consumer examples include Hormel Foods, whose Wholly Guacamole uses an Aptar closure and valve, and McCormick, which launched a spice closure in Mexico. Aptar also works with Bausch + Lomb to develop and industrialize the Beat the Blink dosing technology, which is not yet commercially available.
Aptar has manufacturing and sales operations in North America, Europe, Asia and Latin America. Europe was its largest sales region, accounting for approximately 49% of consolidated sales for the year ended December 31, 2025, based on shipped-to locations. Asia and Latin America combined represented approximately 20% of consolidated sales for that period. Some beauty and pharmaceutical customers export finished products containing Aptar technology around the world.
Suppliers and costs
Aptar’s principal raw materials are plastic resins, silicone, rubber and certain metal products. It uses subcontractors for some plastic and metal components to supplement capacity and improve use of its own facilities. Some component suppliers have unique technical specifications, creating dependence on them, particularly in pump and aerosol-valve production.
The company sources certain materials, including some resins and rubber components for Pharma, from a single source. A delay or discontinuation of an approved material could require an alternative source, raise costs and affect short-term supply. Aptar says it maintains safety stock and has sought dual sources for key materials.
Most production is outside the United States, and Aptar aims to manufacture products in the region where they will be sold. Its facilities use injection molding, automated assembly and elastomer and silicone processing; pharmaceutical production can require clean rooms. The business has relatively high fixed costs, so lower demand can leave plant capacity unused. Input costs, including materials, transportation and energy, can also change rapidly.
Cost of sales, excluding depreciation and amortization, was 62.8% of net sales in 2025, compared with 62.2% in 2024. The increase reflected lower-margin product mix, operational inefficiencies and higher costs for certain inputs.
- Revenue$3.8B
- Cost of revenue−$2.4B
- Selling, general and administrative−$606.5M
- Other operating costs−$297.2M
- Operating income$501.0M
Competitive position
Aptar faces price competition in all product lines and markets, from regional businesses through international companies. Its packaging solutions peers include Albéa and Sonoco. Aptar also faces competition from lower-cost Asian suppliers in Europe, Latin America and the United States, particularly in beauty and personal care.
The company believes its competitive advantages include innovation, quality, regulatory and pharma services, geographic diversity, manufacturing reliability and breadth of products. It seeks patents and trademarks, although it says no single patented product is material to a segment or its consolidated results. Customers also consider local supply, lead times and service when selecting suppliers.
Our reading: Drug-device development and regulatory work provide a meaningful source of customer ties, because Aptar can spend years adapting a device to a customer’s formulation and pharmaceutical manufacturing requires qualification and validation. Our reading: Manufacturing know-how and global facilities offer another advantage, but local and regional competitors remain significant and capital-intensive operations require continued investment. Our reading: Patents and proprietary technology support differentiation across the portfolio, but the absence of a material individually patented product limits reliance on any one patent.
In North American Beauty, Aptar says it has lost market share with certain customers and is subscale in some markets, including indie brands. The company says improving execution there will take time.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Albéa | Packaging solutions | Medium |
| Sonoco | Packaging solutions | Medium |
Growth opportunities
Aptar seeks organic growth by using its existing capabilities and capacity, sharing technologies across segments and focusing on growth regions. It also evaluates acquisitions and partnerships that can extend its technologies, geographic reach and product offerings.
In Pharma, the company sees opportunities in over-the-counter and generic medicines, as well as new drug delivery systems. Its nasal delivery programs include Phase III work in pain management and severe allergic reactions, and Phase II work across neurological diseases, respiratory viral infection prevention and emergency treatment. Aptar has also announced a research collaboration with Massachusetts General Hospital on nose-to-brain delivery.
The company is adding PULMOTREE’s Kolibri non-propellant liquid inhaler technology through an acquisition. It has expanded Pharma operations in Mumbai and introduced Premia Precision, a quality standard for elastomeric components used in complex injectable therapies. A collaboration with Stevanato Group is intended to help customers make packaging decisions for injectable medicines earlier in development.
For consumer markets, Aptar is developing dispensing designs that use less material, are recyclable or incorporate recycled content. The company expects custom capabilities and increased use of pumps in fragrance, skincare and sampling to provide opportunities in Beauty. Closures is also developing products for flexible packaging and features such as tethered caps.
Reported net sales increased 5% in 2025, while core sales increased 2%. In Q3 2026, core sales increased 5% from the prior-year period. Aptar expects its emergency medicine destocking impact to lap in Q4 2026.
- $3.2BFY2021
- $3.3BFY2022
- $3.5BFY2023
- $3.6BFY2024
- $3.8BFY2025
Structural risks
- Customer drug outcomes and regulation: Aptar can spend years adapting a device to a drug formulation. If the customer’s drug is not approved or does not succeed commercially, Aptar may not recover its development investment. Regulatory reviews can also delay product revenue or add costs.
- Supply and manufacturing disruption: Some Pharma materials come from a single source, and certain components depend on a single location, machine or mold. A facility disruption can delay deliveries and launches; pharmaceutical validation and customer qualification can make recovery more difficult.
- Costs and plant utilization: Resin, rubber, metals, energy and transportation costs can rise rapidly, and market conditions may prevent timely price increases. Lower demand can leave capacity unused while fixed costs continue, affecting margins.
- Competition and execution: Aptar faces price competition throughout its markets and must continually develop products to retain and attract customers. In North American Beauty, it has lost share with some customers and says its operational transformation will take time.
- International exposure: Trade restrictions, geopolitical events and currency movements can affect costs, supply and reported results. Aptar lost control of its Russian subsidiary and deconsolidated it effective September 21, 2026, recording a combined charge of $61.2 million before tax.
Bottom line
Our reading
Our reading: Aptar combines a pharmaceutical delivery and packaging business with consumer dispensing operations, with Pharma contributing a larger share of segment earnings than of sales in 2025 (item1). Its customer development work and manufacturing expertise support those businesses, but returns depend on drug launches, plant utilization and the ability to manage input costs (item1a). Recent emergency medicine destocking and North American Beauty difficulties show how product mix and execution can affect results even when sales grow (call_prepared; call_qa).